Skip to content

US · TDOC · MEDICAL - HEALTHCARE INFORMATION SERVICES

Teladoc Health, Inc. (TDOC) intrinsic value and stock valuation

$7.45as of 2026-11-21 · Mkt cap 1.26B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Teladoc Health, Inc. DCF and intrinsic value

InvestorsCraft values TDOC with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from TDOC’s statements →

Teladoc Health, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Healthcare Information Services New York, NY 10577 teladochealth.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$2.53B+18.3% 5y CAGRd
20132025
Net income
-$-200.32M
20132025
Free cash flow
$285.5M
20132025
Total equity
$1.39B-38.6% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$2.53B$2.57B$2.6B$2.41B$2.03B
Operating income-$-262.95M-$-1.02B-$-248.55M-$-13.65B-$-265.63M
Net income-$-200.32M-$-1B-$-220.37M-$-13.66B-$-428.79M
EPSd-$-1.14M-$-5.87M-$-1.34M-$-84.6M-$-2.73M
Operating cash flow$294.4M$293.7M$350M$189.3M$194M
Capital expenditure-$-8.89M-$-10.79M-$-156.35M-$-16.48M-$-8.53M
Free cash flow$285.5M$282.9M$193.7M$172.8M$185.5M
Total assets$3.1B$3.52B$4.39B$4.7B$17.7B
Total debt$1.04B$1.58B$1.59B$1.59B$1.28B
Net debt$259.1M$286.3M$468.6M$668.7M$386.7M
Total equity$1.39B$1.49B$2.33B$2.31B$16B
Cash and short-term investments$781.1M$1.3B$1.12B$918.2M$896M
Income statement
20252024202320222021
Revenue$2.53B$2.57B$2.6B$2.41B$2.03B
Cost of revenue$771.6M$751.3M$760M$744M$650.3M
Gross profit$1.76B$1.82B$1.84B$1.66B$1.38B
Research and development expenses$277.9M$307.3M$348.5M$333.6M$311.9M
Selling, general and administrative expenses$1.09B$1.35B$1.37B$1.3B$1.11B
Other expenses$658.2M$1.19B$375.1M$13.7B$230.9M
Operating expenses$2.02B$2.84B$2.09B$15.3B$1.65B
Cost and expenses$2.79B$3.59B$2.85B$16.1B$2.3B
Interest income$36.8M$57.1M$46.8M$12.7M$780K
Interest expense$19.7M$23.8M$22.3M$21.9M$81.1M
Depreciation and amortization$363.1M$240.5M$254.1M$209.9M$207.6M
Ebitda$147.3M$31.7M$43.6M-$-7.54M-$-31.42M
Operating income-$-262.95M-$-1.02B-$-248.55M-$-13.65B-$-265.63M
Total other income/expenses, net$27.4M$27.2M$29M-$-10.13M-$-119.03M
Income before tax-$-235.53M-$-993.65M-$-219.61M-$-13.66B-$-384.66M
Income tax expense-$-35.21M$7.59M$760K-$-3.81M$44.1M
Net income-$-200.32M-$-1B-$-220.37M-$-13.66B-$-428.79M
Weighted average shares outstanding$176.2M$170.6M$162.2M$161.5M$156.9M
Weighted average diluted shares outstanding$176.2M$170.6M$164.6M$161.5M$156.9M
Balance sheet
20252024202320222021
Cash and short-term investments$781.1M$1.3B$1.12B$918.2M$896M
Net receivables$201.7M$224M$230.1M$235.7M$190.1M
Inventory$38.2M$38.1M$29.5M$56.3M$73.1M
Total current assets$1.09B$1.66B$1.49B$1.29B$1.23B
Property, plant and equipment, net$53.1M$56.6M$72.1M$71.5M$74M
Goodwill and intangible assets$1.58B$1.71B$2.75B$2.91B$16.4B
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.01B$1.85B$2.9B$3.42B$16.5B
Total assets$3.1B$3.52B$4.39B$4.7B$17.7B
Accounts payable$48M$33.1M$43.6M$47.7M$47.3M
Short-term debt$11M$561.1M$10.8M$13.6M$12.7M
Deferred revenue$62.3M$79.3M$95.7M$101.8M$75.6M
Total current liabilities$404.7M$941.5M$420.6M$399.8M$331M
Long-term debt$1.03B$1.02B$1.58B$1.57B$1.27B
Deferred revenue, non-current$9.14M$9.79M$13.6M$12M$3.83M
Total non-current liabilities$1.31B$1.08B$1.65B$1.99B$1.36B
Capital lease obligations$34.2M$42.5M$53.6M$38M$54.5M
Total liabilities$1.72B$2.03B$2.07B$2.39B$1.69B
Common stock$180K$170K$170K$160K$160K
Retained earnings-$-16.43B-$-16.23B-$-15.23B-$-15.01B-$-1.42B
Accumulated other comprehensive income (loss)-$-34.73M-$-38.39M-$-36.99M-$-42.78M-$-6.29M
Total equity$1.39B$1.49B$2.33B$2.31B$16B
Total investments$0.00$0.00$0.00$0.00$2.54M
Total debt$1.04B$1.58B$1.59B$1.59B$1.28B
Net debt$259.1M$286.3M$468.6M$668.7M$386.7M
Cash flow statement
20252024202320222021
Net income-$-200.32M-$-1B-$-220.37M-$-13.66B-$-428.79M
Depreciation and amortization$363.1M$382.8M$348.7M$267.8M$219.6M
Stock-based compensation$80.4M$146M$201.6M$217.9M$302.6M
Change in working capital$1.07M-$-36.31M$11.6M-$-48.39M-$-43.99M
Accounts receivable$25.1M-$-380K-$-10.25M-$-49.06M-$-11.17M
Inventory$400K-$-9.75M$24.1M$14.8M-$-19.49M
Accounts payable$11.5M-$-10.37M-$-4.18M$1.88M$1.19M
Net cash provided by operating activities$294.4M$293.7M$350M$189.3M$194M
Investments in property, plant and equipment-$-8.89M-$-10.79M-$-156.35M-$-172.76M-$-63.93M
Acquisitions, net-$-81.9M$0.00$0.00$0.00-$-78.66M
Net cash used for investing activities-$-266M-$-124.05M-$-156.35M-$-167.74M-$-72.98M
Common stock issued$3.08M$8.31M$11.1M$12.4M$42.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-551.65M$8.31M$10.9M$6.5M$41M
Net change in cash-$-517.24M$174.7M$205.5M$24.7M$160.2M
Cash at end of period$781.1M$1.3B$1.12B$918.2M$893.5M
Operating cash flow$294.4M$293.7M$350M$189.3M$194M
Capital expenditure-$-8.89M-$-10.79M-$-156.35M-$-16.48M-$-8.53M
Free cash flow$285.5M$282.9M$193.7M$172.8M$185.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Teladoc Health, Inc.

        Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.

        CEO
        Charles Divita
        Employees
        5.6K
        Beta
        2.10

        Explore

        Frequently asked questions

        What is the intrinsic value of Teladoc Health, Inc. (TDOC)?

        Teladoc Health, Inc. (TDOC) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TDOC undervalued?

        TDOC trades at a price of $7.45 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.